更正：穆谢拉克等人。CA-170——一种有效的小分子PD-L1抑制剂？2019年，，2804。 （你提供的原文中部分内容缺失或格式有误，可能影响准确理解，以上是按现有内容尽量完整翻译的结果 ）
Correction: Musielak et al. CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not? 2019, , 2804.
作者信息
Musielak Bogdan, Kocik Justyna, Skalniak Lukasz, Magiera-Mularz Katarzyna, Sala Dominik, Czub Miroslawa, Stec Malgorzata, Siedlar Maciej, Holak Tad A, Plewka Jacek
机构信息
Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland.
Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, Wielicka 265, 30-663 Krakow, Poland.
出版信息
Molecules. 2025 Apr 18;30(8):1816. doi: 10.3390/molecules30081816.
Abstract
There was an error in the original publication [...].
摘要
原始出版物中存在一处错误[……]。
相似文献
1
Correction: Musielak et al. CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not? 2019, , 2804.
Molecules. 2025 Apr 18;30(8):1816. doi: 10.3390/molecules30081816.
2
CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?
Molecules. 2019 Aug 1;24(15):2804. doi: 10.3390/molecules24152804.
3
Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. 2020, , 666.
Cancers (Basel). 2025 Apr 8;17(8):1254. doi: 10.3390/cancers17081254.
4
Correction: Aksic et al. The Neuroprotective Effect of Neural Cell Adhesion Molecule L1 in the Hippocampus of Aged Alzheimer's Disease Model Mice. 2024, , 1726.
Biomedicines. 2025 Jan 24;13(2):290. doi: 10.3390/biomedicines13020290.
5
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Cancer Discov. 2022 Jun 2;12(6):1482-1499. doi: 10.1158/2159-8290.CD-21-1156.
6
Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors.
J Zhejiang Univ Sci B. 2023 Oct 15;24(10):935-942. doi: 10.1631/jzus.B2200631.
7
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.
Commun Biol. 2021 Jun 8;4(1):699. doi: 10.1038/s42003-021-02191-1.
8
Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interaction.
ChemMedChem. 2021 Sep 16;16(18):2769-2774. doi: 10.1002/cmdc.202100264. Epub 2021 Jun 29.
9
Correction: Konstantopoulos et al. HPV16 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway. 2024, , 113.
Viruses. 2024 Nov 22;16(12):1817. doi: 10.3390/v16121817.
10
A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Front Immunol. 2021 May 14;12:654463. doi: 10.3389/fimmu.2021.654463. eCollection 2021.
本文引用的文献
1
CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?
Molecules. 2019 Aug 1;24(15):2804. doi: 10.3390/molecules24152804.
Zotero 插件